<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269996</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2010.523</org_study_id>
    <nct_id>NCT01269996</nct_id>
  </id_info>
  <brief_title>JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients</brief_title>
  <acronym>JUBILEE</acronym>
  <official_title>JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of a new treatment regimen of metformin plus sitagliptin&#xD;
      (Janumet) followed by a long-acting basal insulin (Lantus) treatment compared to the usual&#xD;
      treatment regimen of metformin followed by sulfonylurea and intermediate-acting basal insulin&#xD;
      in Type 2 Diabetes Mellitus patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) accounts for more than 90% of all diabetes. The worldwide&#xD;
      prevalence of T2DM is increasing.&#xD;
&#xD;
      Microvascular and macrovascular complications are well known to cause significant morbidities&#xD;
      and shorten life expectancy in diabetic patients. T2DM is the leading cause of adult-onset&#xD;
      blindness, renal failure, limbs amputation, ischaemic heart disease and stroke in the&#xD;
      industrialized world. Progressive pancreatic beta-cell failure together with insulin&#xD;
      resistance underlie the pathogenesis of T2DM.&#xD;
&#xD;
      Glycaemic control is essential and fundamental to the management of diabetes. Randomized&#xD;
      control trials have confirmed the long term benefits of achieving glycaemic control early in&#xD;
      the course of disease on future clinical outcomes. Long term follow up of The Diabetes&#xD;
      Control and Complications Trial Research Group (DCCT) and U.K. Prospective Diabetes Study&#xD;
      (UKPDS) cohorts showed that improving glycaemic control reduces the incidences of both&#xD;
      microvascular and macrovascular complications.&#xD;
&#xD;
      It is generally agreed that HbA1c &lt;7% is a reasonable goal in adults to reduce risk of&#xD;
      diabetes complications. Subgroup analyses of DCCT and UKPDS and results of Action in Diabetes&#xD;
      and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE)&#xD;
      trial suggest a small but incremental benefit in microvascular outcomes with HbA1c values&#xD;
      closer to normal. In the subgroup analysis of the ACCORD study, subjects without history of&#xD;
      cardiovascular disease and attained HbA1c goal of 6.5% had lower risk of cardiovascular&#xD;
      endpoints than those with HbA1c goal of 7%. Therefore, selected individual patients including&#xD;
      those with short duration of diabetes, long life expectancy and no significant cardiovascular&#xD;
      disease, may benefit from a more stringent HbA1c goal of &lt;6.5%, a value close to normal&#xD;
      individual.&#xD;
&#xD;
      According to the American Diabetes Association (ADA) and the European Association for the&#xD;
      Study of Diabetes, lifestyle modification plus Metformin is a well-validated step 1 therapy&#xD;
      for patients with T2DM. Sulfonylurea or insulin treatment formed the step 2 therapy in those&#xD;
      who fail to achieve optimal glycaemic control after step 1 treatment. Sulfonylurea is an&#xD;
      insulin secretagogue. It acts in a glucose-independent fashion by increasing the insulin&#xD;
      concentration irrespective of the ambient glucose concentration. Despite its efficacy, it is&#xD;
      associated with increased risk of hypoglycaemia and weight gain.&#xD;
&#xD;
      Incretins are gut-derived hormones that include Glucagon-like peptide-1 (GLP-1) and&#xD;
      Glucose-dependent insulinotropic peptide (GIP). Incretins are released into the circulation&#xD;
      after a meal. Both GLP-1 and GIP stimulate endogenous insulin secretion in a&#xD;
      glucose-dependent fashion. They also inhibit glucagon secretion, delay gastric emptying and&#xD;
      induce satiety. The combined effect of incretins in augmenting insulin secretion and&#xD;
      suppressing glucagon reduces post-prandial glucose excursion. In animal models, GLP-1 has&#xD;
      also been shown to preserve pancreatic beta-cell mass by increased proliferation and&#xD;
      decreased apoptosis. In T2DM patients, the attenuated post-prandial GLP-1 secretion may&#xD;
      partially explain the increased post-prandial rise in glucose concentration.&#xD;
&#xD;
      However, incretins have very short half-lives of a few minutes. They are rapidly inactivated&#xD;
      by the enzyme dipeptidyl peptidase IV (DPP-4) in the circulation. Inhibitors of the enzyme&#xD;
      DPP-4 can augment active incretin levels by delaying the clearance of the active incretins,&#xD;
      hence augmenting the incretin action with resultant improvement in glycaemic control in T2DM&#xD;
      patients.&#xD;
&#xD;
      In later stage of T2DM, progressive pancreatic beta-cell failure frequently results in&#xD;
      deterioration in glycaemic control despite oral drug treatment, necessitating supplementary&#xD;
      insulin therapy. New generations of once-daily, long-acting basal insulin may have better&#xD;
      safety profile in terms of less hypoglycaemic events compared with traditional&#xD;
      intermediate-acting basal insulin. Supplementary basal insulin, when titrated appropriately,&#xD;
      will almost always improve fasting blood glucose levels and HbA1c control.&#xD;
&#xD;
      Sitagliptin is an orally active, potent and highly selective DPP-4 inhibitor which was&#xD;
      approved by the U.S. Food and Drug Administration (FDA) in October 2006 as a new class of&#xD;
      oral drug treatment for T2DM. Sitagliptin is marketed as Januvia by Merck &amp; Co. In April&#xD;
      2007, the FDA approved an oral combination of sitagliptin and metformin marketed as Janumet&#xD;
      with preparations of 50/500mg and 50/1000mg dosage per tablet. Sitagliptin has been proved to&#xD;
      be effective in treating T2DM with minimal risk of hypoglycaemia together with additional&#xD;
      benefits on reducing glucagon, slowing gastric emptying and inducing satiety.&#xD;
&#xD;
      Insulin glargine, marketed by Sanofi Aventis under the name Lantus, is a long-acting basal&#xD;
      insulin analogue. It has the advantage of a long action duration of 18 to 26 hours and a&#xD;
      peakless profile, which resembles basal insulin secretion of non-diabetic pancreatic&#xD;
      beta-cells.&#xD;
&#xD;
      In T2DM patients, we proposed that a new treatment regimen consists of a combination of&#xD;
      DPP-IV inhibitor plus metformin followed by long-acting basal insulin may be more effective&#xD;
      in achieving good and sustained glycaemic control with less hypoglycaemic drawbacks compared&#xD;
      with the traditional regimen of metformin followed by sulfonylurea and finally&#xD;
      intermediate-acting insulin. This proposed new treatment regimen forms the basis of this&#xD;
      study.&#xD;
&#xD;
      The objective of this multicentre, randomized, open-label prospective study is to evaluate&#xD;
      the efficacy and safety of a new treatment regimen of metformin plus sitagliptin (Janumet)&#xD;
      followed by a long-acting basal insulin (Lantus) treatment compared to the usual treatment&#xD;
      regimen of metformin follow by sulfonylurea and intermediate-acting basal insulin in T2DM&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the treatment efficacy</measure>
    <time_frame>one year</time_frame>
    <description>The change in HbA1c in 1 year compare to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with HbA1c &lt;6.5% in 1 year</measure>
    <time_frame>one year</time_frame>
    <description>Secondary Outcome Measure: The proportion of patients with HbA1c &lt;6.5% in 1 year.&#xD;
Other outcome measures: a)The change in body weight compare to baseline. b)Frequency of hypoglycaemia . Hypoglycemia is defined according to the ADA definitions and classifications of hypoglycaemia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin followed by gliclazide and protaphane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Janumet followed by Lantus insulin injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Janumet, Lantus</intervention_name>
    <description>In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.&#xD;
Treatment groups:&#xD;
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.&#xD;
Group 2 - Janumet followed by Lantus insulin injection.</description>
    <arm_group_label>Janumet followed by Lantus insulin injection</arm_group_label>
    <arm_group_label>Metformin followed by gliclazide and protaphane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin, gliclazide, protaphane</intervention_name>
    <description>In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.&#xD;
Treatment groups:&#xD;
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.&#xD;
Group 2 - Janumet followed by Lantus insulin injection.</description>
    <arm_group_label>Janumet followed by Lantus insulin injection</arm_group_label>
    <arm_group_label>Metformin followed by gliclazide and protaphane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients aged 18 to 80 years old at Visit 1.&#xD;
&#xD;
          2. Male or female of Chinese ethnicity.&#xD;
&#xD;
          3. Type 2 diabetic patients who are drug na√Øve with HbA1c ranged between 7.0% to 11.0%.&#xD;
&#xD;
          4. Type 2 diabetic patients who are on single oral hypoglycaemic drug treatment or&#xD;
             insulin treatment of duration less than 6 months are eligible after at least 3 months&#xD;
             of washout period with diet control only prior to Visit 1 and satisfy the inclusion&#xD;
             criteria of HbA1c ranged between 7.0% to 11.0%.&#xD;
&#xD;
          5. Patient understands the study procedures, alternative treatments available, and the&#xD;
             risks involved with the study, and voluntarily agrees to participate by providing&#xD;
             written informed consent.&#xD;
&#xD;
          6. Patient agrees to provide permission to obtain all medical records necessary for&#xD;
             complete data ascertainment during study and follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis.&#xD;
&#xD;
          2. Patients with HbA1c 9% to 11% who have severe symptoms and showing signs of&#xD;
             decompensation (e.g. rapid weight loss and ketonuria) due to hyperglycaemia.&#xD;
&#xD;
          3. On anti-obesity drugs 12 weeks prior to informed consent, patient in a weight loss&#xD;
             program or intends to be involved in weight loss intervention outside that prescribed&#xD;
             by the study.&#xD;
&#xD;
          4. Patient has renal impairment defined as serum creatinine equal to/more than 123 umol/l&#xD;
             (1.4mg/dL) in female and serum creatinine equal to/more than 132 umol/l (1.5mg/dL) in&#xD;
             male.&#xD;
&#xD;
          5. Significant liver impairment (ALT equal to /more than 2 times upper limit of normal&#xD;
             range) or a medical history of active liver disease (other than non-alcoholic hepatic&#xD;
             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis,&#xD;
             liver cirrhosis or symptomatic gallbladder disease.&#xD;
&#xD;
          6. Any history of cardiovascular disease, stroke or peripheral vascular disease.&#xD;
&#xD;
          7. Any symptoms of ischaemic heart disease like angina.&#xD;
&#xD;
          8. Renal transplant patients.&#xD;
&#xD;
          9. Active malignant disease. Patients with malignant disease who have been successfully&#xD;
             treated and disease-free for at least 5 years are eligible. However, patients with a&#xD;
             history of leukaemia, lymphoma, aplastic anaemia, myeloproliferative or&#xD;
             myelodysplastic disease, thrombocytopenia, malignant melanoma, or renal cell carcinoma&#xD;
             are ineligible for the study regardless of the time since treatment.&#xD;
&#xD;
         10. Patient has medical history that indicates a life expectancy of less than 5 years or&#xD;
             might limit the individual's ability to take trial treatments for the duration of the&#xD;
             study.&#xD;
&#xD;
         11. Patient has a history or current evidence of any condition, therapy, laboratory&#xD;
             abnormality, or other circumstance which, in the opinion of the investigator or&#xD;
             coordinator, might pose a risk to the patient, make participation not in the patient's&#xD;
             best interest, confound the results of the study (e.g. if patient cannot comply with&#xD;
             requirements of the study), or interfere with the patient's participation for the full&#xD;
             duration of the study.&#xD;
&#xD;
         12. Patient has a known history of hypersensitivity, intolerance or any contraindication&#xD;
             to either metformin, sulfonylurea, DPP-IV inhibitor or insulin.&#xD;
&#xD;
         13. Active and uncontrolled thyroid diseases or active endocrine diseases like Cushing's&#xD;
             syndrome or acromegaly.&#xD;
&#xD;
         14. Pre-menopausal women (last menstruation 1 year prior to signing informed consent) who:&#xD;
             are nursing or pregnant, or are of child-bearing potential and are not practicing an&#xD;
             acceptable and reliable contraceptive methods, or do not plan to continue using this&#xD;
             method throughout the study and do not agree to submit to periodic pregnancy testing&#xD;
             during participation in the trial. Acceptable methods of birth control include&#xD;
             transdermal patch, intra-uterine devices/systems (IUDs/IUSs), oral, implantable or&#xD;
             injectable contraceptives, sexual abstinence and vasectomised partner. No exception&#xD;
             will be made.&#xD;
&#xD;
         15. Any medical illness or condition as judged by the investigators as ineligible to&#xD;
             participate the study.&#xD;
&#xD;
         16. Special population, e.g. prisoner, mentally disabled, persons with psychiatric&#xD;
             disorders and investigators' student or employees.&#xD;
&#xD;
         17. Patient is currently participating in or has participated in another study with an&#xD;
             investigational compound or device within the prior 12 weeks of screening or signing&#xD;
             the informed consent and does not agree to refrain from participating in any other&#xD;
             study while participating in this study.&#xD;
&#xD;
         18. Patient has undergone surgery within the prior 12 weeks or has major surgery planned&#xD;
             during the study.&#xD;
&#xD;
         19. Patient is on or is likely to require treatment with equal to/ more than 14&#xD;
             consecutive days or repeated courses of pharmacologic doses of corticosteroids.&#xD;
&#xD;
             Note: Inhaled, nasal, and topical corticosteroids are permitted.&#xD;
&#xD;
         20. Patient has a clinically significant laboratory or ECG abnormality which, in the&#xD;
             opinion of the investigator, exposes the patient to risk by enrolling in the study.&#xD;
&#xD;
         21. History of drug abuse or alcohol abuse. History of recreational or illicit drugs used.&#xD;
             Alcohol abuse includes heavy alcohol intake as defined by more than 2 drinks per day&#xD;
             or more than 14 drinks per week, or binge drinking.&#xD;
&#xD;
         22. Patient has a clinically significant haematological disorder (e.g., aplastic anaemia,&#xD;
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia, thalassaemia or&#xD;
             thalassaemia trait).&#xD;
&#xD;
         23. Blood donation 3 months prior to the start of the study and during the whole study&#xD;
             period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana CN CHAN, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine &amp; Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Juliana Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>JUBILEE Study</keyword>
  <keyword>Janumet</keyword>
  <keyword>Lantus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

